ClinicalTrials.gg
Active, not recruitingNCT05114798Updated Jul 21, 2026

Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers

An interventional study of Time restricted eating and Calorie Restriction in Time Restricted Eating, Obesity and Weight Loss, sponsored by University of Illinois at Chicago. Active, not recruiting at 1 site in United States. Open to participants aged 45 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by University of Illinois at Chicago · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
194
Allocation
Randomized
Ages
45 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 113 studies in Intermittent Fasting with a site in United States — 33 open to participants now, 44 under way, none of them phase 3. Intermittent Fasting · United States.

Enrollment
2nd of 112
194 · median 40
Started
2022
with 13 others
No phase
104 of 113
26 open now
Primary completion
2027-03
later than 19 of 43 live
Registered
47th of 113
by date
Lead sponsor
5 of 113
University of Illinois at Chicago

Among the 113 studies in Intermittent Fasting with a site in United States, this one is the 2nd largest by enrollment of the 112 interventional ones that give a count, is one of 14 that started in 2022, is one of 104 with no phase, reaches primary completion later than 19 of the 43 other live ones, and was the 47th registered.

Intermittent Fasting

334 studies on the registry are indexed under Intermittent Fasting; 100 are open to participants now.

Browse Intermittent Fasting studies →

Open to participants now

33 of the 113 studies in Intermittent Fasting with a site in United States are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 74 Intermittent Fasting studies recruiting now, 19 (26%) set no upper age limit and 49 (66%) stop at 75 or younger; 4 take children under 18; 22 take healthy volunteers.

This study: 45 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies in Intermittent Fasting with a site in United States, or all of them as a file.
02

Study summary

Approximately 42% of American adults are obese, and this condition is strongly related to the development of colorectal cancer. Innovative lifestyle strategies to treat obesity and reduce colorectal cancer risk are critically needed. This research will demonstrate that time-restricted eating, a type of intermittent fasting, is an effective therapy to help obese individuals reduce and control their body weight and prevent the development of colorectal cancer.

Read the detailed description

Approximately 42% of the U.S. adult population is obese and data suggests that persons with obesity are at a 30% greater risk of developing colorectal cancer (CRC). Therefore, efficacious approaches to preventing and treating obesity will have significant effects on CRC incidence in the U.S. Although calorie restriction through lifestyle intervention is the most common approach to treat obesity, clinically meaningful weight loss is difficult to achieve via this method due to low adherence with calorie monitoring, indicating a need for innovation. Time-restricted eating, a type of intermittent fasting, has been shown in animals to impart cancer protective effects including lower body weight, decreased systemic inflammation, and improved glucose metabolism. Time-restricted eating is where individuals are asked to consume all their food for the day within a specified time frame, and water fast for the remaining hours of the day. We recently performed two short-term (≤12-weeks) pilot studies of time-restricted eating to evaluate its safety and preliminary efficacy on body weight and chronic disease risk markers in adults with obesity. Our results show the intervention is a safe and acceptable approach to weight loss among obese adults. Moreover, time-restricted eating produced approximately 3% weight loss from baseline and reductions in systolic blood pressure, oxidative stress and insulin resistance. Although these pilot findings show promise for time-restricted eating as an effective tool for CRC risk reduction among obese individuals, these data still require confirmation by a well powered longer-term clinical trial. The present proposal aims to implement a 12-month (6-month intervention, 6-month maintenance) controlled, parallel arm trial among 255 obese adults (45-70 years old) who have had a colonoscopy. Subjects will be randomized to 1 of 3 groups: 1) 8-hour time-restricted eating (daily ad libitum food intake from 12pm - 8pm), 2) Calorie restriction (daily 25% calorie restriction), or 3) Control (daily ad libitum food intake, no meal timing restrictions) to compare the effects on: (1) Body weight, body composition, and intervention adherence; (2) Circulating metabolic, inflammation, and oxidative stress-related biomarkers; (3) Colonic mucosal gene expression profiles and mucosal inflammation, DNA damage and cellular growth; and (4) maintenance of benefits on body weight/composition and CRC markers.

03

Conditions studied

  • Time Restricted Eating
  • Obesity
  • Weight Loss
  • Colorectal Cancer
04

Who can participate

Ages eligible
45 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 45-70 years old,
  2. 30-49.99 kg/m2
  3. Are up to date with CRC screening.

Exclusion criteria

Exclusion Criteria:

  1. Have a history of renal disease, disorders, immunodeficiency, malabsorptive disorder, significant gastrointestinal and hepatic disease, surgical change in gastrointestinal anatomy, severe ischemic heart disease, severe pulmonary disease, severe mental health disorder, eating disorder, or bariatric surgery;
  2. Abuse alcohol (> 50 grams/day), illicit drugs (other than self-reported marijuana use), or use combustible tobacco;
  3. Have controlled type 2 diabetes or undiagnosed uncontrolled diabetes based on (HbA1c) > 9.0%;
  4. Have a history of cancer treatment within the past 12 months, CRC, genetic predisposition to CRC (e.g., Lynch syndrome);
  5. Have a baseline body weight > 450 lbs (weight limitation of the DXA);
  6. Are on a weight loss diet or actively involved in a formal weight loss program (e.g., Weight Watchers);
  7. Are not weight stable for 3 months prior to the study (weight gain or loss > 4 kg);
  8. Are unable to keep a food diary for 7 consecutive days during screening;
  9. Are night shift workers;
  10. Are pregnant or trying to get pregnant;
  11. Are taking drugs that influence study outcomes (weight loss medications);
  12. Are non-English speaking
  13. Are taking anticoagulant medications or medications with endoscopic risk
  14. Are taking antivirals or medications
  15. Don't have regular access to an email address and computer/smartphone/tablet
  16. Are currently following a diet that requires fasting on a weekly basis
  17. Currently eat for less than 10 hours of the day (determined by asking participants what time they start and stop eating on a usual day)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
194 participants (actual)

Study arms

  • Experimental
    Time Restricted Eating (TRE)

    During the active weight loss period, the TRE group will be instructed to eat ad libitum from 12:00pm - 8:00pm daily and fast from 8:00pm - 12:00pm. During the 8-h eating window, there will be no restrictions on types or quantities of foods consumed. During the fasting period, participants will be encouraged to drink plenty of water and may consume energy-free beverages, such as black tea or coffee. TRE subjects will meet with the TRE dietitian for 30 minutes at the start of the intervention to review instructions and goals, and then every week throughout the active weight loss period to review intervention adherence. At the beginning of the maintenance phase, total energy needs will be reassessed. Subjects will be instructed to main their body weight by consuming meals in an extended 10-h eating window every day and water fast between 8pm and 10 am, respectively.

    Behavioral: Time restricted eating

  • Active comparator
    Calorie Restriction (Cal-R)

    Cal-R subjects will be instructed to restrict energy intake by 25% of their baseline total energy expenditure (TEE) daily. Subjects will meet with a study dietitian for a 60-min one-on-one session to develop individualized weight loss meal plans to help them adhere to their calorie restriction goal. Meal plans will include portion sizes and food lists that are consistent with their food preferences and prescribed calorie levels for weight loss. Food scales will be provided to help with food portioning. Cal-R subjects will meet with the dietitian every week throughout the weight loss period to review intervention adherence and modify the meal plans as needed. Subjects will be asked to maintain their baseline level of physical activity. At the beginning of the weight maintenance phase, total energy needs will be reassessed.

    Behavioral: Calorie Restriction

  • No intervention
    Control

    Controls will be instructed to maintain their weight throughout the 12 m trial and to not change eating or physical activity habits. Controls will not receive dietary counseling. Controls will visit the research center every 3 months for outcome measurements.

Interventions

  • BehavioralTime restricted eating

    daily ad libitum food intake, 8-h 12pm - 8pm, 6 m active weight loss phase; 10-h 10am-8pm, 6 m maintenance phase

  • BehavioralCalorie Restriction

    daily 25% calorie restriction, 6 m active weight loss phase; 100% energy needs, 6 m maintenance phase

06

What researchers measure

Primary outcomes

  1. Weight change (% kg)

    Body weight in kg

    Time frame: Baseline to month 6

Secondary outcomes

  1. Total and regional body fat composition and distribution

    Total and regional body fat composition and distribution will be measured via whole body DEXA scan

    Time frame: Baseline, 6 month and 12 month

  2. Intervention adherence

    Measured through electronic diet records and 24 hour dietary recalls

    Time frame: Monthly, through month 6

  3. Fasting serum glucose

    From fasting venous blood measured by a commercial lab

    Time frame: Baseline, month 3, month 6, month 9, month 12

  4. Plasma cytokines TNF-α, IL-6, IL1-β, and IL-10, %

    Multiplex ELISA

    Time frame: Baseline, month 3, month 6, month 9, month 12

  5. Plasma 8-isoprostane

    ELISA

    Time frame: Baseline, month 3, month 6, month 9, month 12

  6. Colonic mucosa gene expression profiling

    Commercially available targeted transcriptomics platform

    Time frame: Baseline, month 6, month 12

  7. Ki-67, proliferation

    Healthy colonic mucosa, immunohistochemistry

    Time frame: Baseline, month 6, month 12

  8. c-caspase-3, Bax, apoptosis

    Healthy colonic mucosa, immunohistochemistry,

    Time frame: Baseline, month 6, month 12

  9. CD3, CD163, pIKKa/b, tissue markers of inflammation

    Healthy colonic mucosa, immunohistochemistry

    Time frame: Baseline, month 6, month 12

  10. Weight maintenance (% kg)

    Maintenance of weight loss

    Time frame: Month 6 to month 12

  11. Fasting serum insulin

    From fasting venous blood measured at a commercial lab

    Time frame: Baseline, month 3, month 6, month 9, month 12

  12. HOMA-IR

    calculated from fasting glucose and insulin using a standard formula

    Time frame: Baseline, month 3, month 6, month 9, month 12

  13. Gut Microbiome

    Shotgun metagenomics

    Time frame: Baseline, month 3 and month 6

  14. Fecal Metabolites

    Untargeted Metabolomics

    Time frame: Baseline, month 3 and month 6

  15. Saliva microbiota

    Untargeted Metabolomics

    Time frame: Baseline, month 3, month 6

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for Mar 2027, 58 months after the start.

Of 259 non-industry interventional studies with no phase under Intermittent Fasting, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 34. This study's planned 58 months is above that.

Counting every sponsor, half of 265 studies reached it within 17 months; a quarter within 8 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2021
First posted
Nov 10, 2021
StartActual
May 17, 2022
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2027
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05114798
Responsible party
Lisa Tussing-Humphreys (Professor, University of Illinois at Chicago) — Principal investigator
First posted
Nov 10, 2021
Start date
May 17, 2022
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Jul 21, 2026

Study contacts

Lisa Tussing-Humphreys, PhD, MS, RD
principal investigator · University of Illinois at Chicago

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion